Aptar Reports Fourth Quarter and Annual 2021 Results
Fourth Quarter 2021 Summary: *Strong top line growth across each segment resulted in reported sales up 9% and core sales (excluding currency effects and acquisitions) up 10% *Reported earnings per share increased 8% to $0.85 *Reported net income increased 8% to $58 million. Annual 2021 Summary: *Top line growth across each segment drove record annual sales of $3.2 billion *Reported sales grew 10% and core sales increased 7% *Reported net income totaled $244 million, exceeding 2019 pre-pandemic levels *Acquired Voluntis, a pioneer in digital therapeutics, and 80% of Weihai Hengyu Medical Products, a leading Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery *Furthered our ESG performance and commitments resulting in the following recognitions: Newsweek’s Most Responsible Companies, Barron’s Most Sustainable Companies, Forbes’ Green Growth 50 list, Forbes’ Global Top 10 Female-Friendly Companies, JUST Capital’s Top 10 Companies Leading in Reducing Environmental Impact, EcoVadis Platinum and CDP’s Supplier Engagement Leaderboard *28th consecutive year of paying increased annual cash dividends